Benitec Biopharma (BNTC) Free Cash Flow (2019 - 2025)

Benitec Biopharma has reported Free Cash Flow for 7 years, with the latest figure at -$3.7 million in Q4 2025.

• Quarterly Free Cash Flow rose 51.97% year-over-year to -$3.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$18.4 million (up 15.42% YoY) and the FY2025 annual result came in at -$23.6 million, down 20.63% from the prior year.
• Free Cash Flow declined to -$3.7 million in Q4 2025 per BNTC's latest filing, from -$3.4 million in the prior quarter.
• Over five years, Free Cash Flow peaked at -$2.0 million in Q1 2021 and troughed at -$8.2 million in Q2 2025.
• A 5-year average of -$4.6 million and a median of -$4.2 million in 2021 frame the typical range for Free Cash Flow.
• The sharpest annual moves came in 2021 and 2025: Free Cash Flow slumped 160.6% in 2021, then surged 51.97% in 2025.
• Over 5 years, Free Cash Flow stood at -$3.3 million in 2021, then slumped by 77.42% to -$5.9 million in 2022, then increased by 9.48% to -$5.3 million in 2023, then plunged by 45.34% to -$7.7 million in 2024, then soared by 51.97% to -$3.7 million in 2025.
• According to Business Quant data, Free Cash Flow over the past three periods registered -$3.7 million, -$3.4 million, and -$8.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.